Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RXRB | P28702 | 8/20 | 1.00 |
| ▸ | RXRG | P48443 | 8/20 | 1.00 |
| ▸ | RARB | P10826 | 5/20 | 1.00 |
| ▸ | RARG | P13631 | 5/20 | 1.00 |
| ▸ | RARA | P10276 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | ESR1 | P03372 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | HTR1A | P08908 | 1/20 | 0.74 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | DRD1 | P21728 | 1/20 | 0.74 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054740 | 1.00 | RXRA (1.00) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL12181011 | 0.94 | RXRA (0.88) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL16926898 | 0.91 | RXRA (0.83) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL292500 | 0.91 | RXRA (0.83) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL5540253 | 0.89 | RXRA (0.80) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6906197 | 0.88 | RXRA (0.79) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL2591205 | 0.88 | RXRA (0.78) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL14212719 | 0.87 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL4910483 | 0.86 | RXRA (0.76) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL1073920 | 0.86 | RXRA (1.00) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263821-A1 | Treatment Of Increased Lipid Levels With Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) Inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE | 2023-08-24 | — | — | US | claimed |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | MELIOR PHARMACEUTICALS I, INC. | 2021-11-25 | — | — | US | claimed |
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2021-06-15 | — | — | US | claimed |
| US-20190321362-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2019-10-24 | — | — | US | claimed |
| US-10251883-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2019-04-09 | — | — | US | claimed |
| US-20180125845-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2018-05-10 | — | — | US | claimed |
| US-9763945-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2017-09-19 | — | — | US | claimed |
| US-20160136165-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | CAVALRY FUND I LP | 2016-05-19 | — | — | US | claimed |
| US-8343985-B2 | Methods for modulating Lyn kinase activity and treating related disorders | MELIOR PHARMACEUTICALS I, INC. (US) | 2013-01-01 | — | — | US | claimed |
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| US-6028052-A | FOR INCREASING GLUCOSE UPTAKE IN ADIPOSE OR MUSCLE TISSUE, COMPRISING THE STEP OF ADMINISTERING TO SAID TISSUE A COMPOSITION COMPRISING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF AN RXR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2000-02-22 | — | — | US | claimed |
| US-6004987-A | ANTIINFLAMMATORY AGENTS FOR MAMMALS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-12-21 | — | — | US | claimed |
| EP-0678086-B1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999056740-A1 | ASSAY FOR IDENTIFICATION OF COMPOUNDS THAT PROMOTE MELANIN PRODUCTION AND RETINOID-LIKE COMPOUNDS IDENTIFIED BY SAID ASSAY | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-11-11 | — | — | WO | claimed |
| US-5972881-A | TREATING HYPERTRIGLYCERIDEMIA, NON-INSULIN-DEPENDENT DIABETES MELLITUS USING A RETINOID X RECEPTOR AGONIST ALONE OR IN COMBINATION WITH A PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-26 | — | — | US | claimed |
| EP-0694301-B1 | Synergistic combination containing at least a RXR specific ligand and a RAR alpha specific ligand | CIRD GALDERMA (FR) | 1996-11-13 | — | — | EP | claimed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | claimed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033548-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | RXRA 1212/4885RXRB 1230/4885RXRG 943/4885 |
| US-20210361652-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1211/4885RXRB 1241/4885RXRG 950/4885 |
| US-20180125845-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRB 1230/4885RXRG 943/4885 |
| US-10251883-B2 | Methods and formulations for modulating Lyn kinase activity and treating related disorders | LYN, FYN, LPL | RXRA 1212/4885RXRB 1230/4885RXRG 943/4885 |
| US-20160136165-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRB 1230/4885RXRG 943/4885 |
| US-20190321362-A1 | Methods And Formulations For Modulating Lyn Kinase Activity And Treating Related Disorders | LYN, FYN, LPL | RXRA 1212/4885RXRB 1230/4885RXRG 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.